login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
PANBELA THERAPEUTICS INC (PBLA) Stock News
USA
- NASDAQ:PBLA -
US69833W4042
-
Common Stock
1.11
USD
-0.12 (-9.76%)
Last: 3/6/2024, 8:15:57 PM
1.04
USD
-0.07 (-6.31%)
After Hours:
3/6/2024, 8:15:57 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PBLA Latest News, Press Relases and Analysis
All
Press Releases
a year ago - By: Panbela Therapeutics, Inc.
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
a year ago - By: Panbela Therapeutics, Inc.
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
a year ago - By: BusinessInsider
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
a year ago - By: InvestorPlace
PBLA Stock Earnings: Panbela Therapeutics Beats EPS for Q2 2024
a year ago - By: BusinessInsider
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024
1 years ago - By: BusinessInsider
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023
1 years ago - By: Benzinga
Recap: Panbela Therapeutics Q4 Earnings
a year ago - By: Panbela Therapeutics, Inc.
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
a year ago - By: Panbela Therapeutics, Inc.
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
a year ago - By: Panbela Therapeutics, Inc.
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
1 years ago - By: Benzinga
Earnings Preview: Panbela Therapeutics
a year ago - By: InvestorPlace
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024
a year ago - By: Panbela Therapeutics, Inc.
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
a year ago - By: Panbela Therapeutics, Inc.
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
a year ago - By: Panbela Therapeutics, Inc.
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
a year ago - By: Panbela Therapeutics, Inc.
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
a year ago - By: Panbela Therapeutics, Inc.
Panbela Announces Poster Presentation at American Association for Cancer Research:
a year ago - By: Panbela Therapeutics, Inc.
Panbela Announces Transfer to OTCQB Market
1 years ago - By: InvestorPlace
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023
2 years ago - By: Panbela Therapeutics, Inc.
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
2 years ago - By: Panbela Therapeutics, Inc.
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
2 years ago - By: Seeking Alpha
Panbela Therapeutics regains compliance with Nasdaq (NASDAQ:PBLA)
2 years ago - By: Panbela Therapeutics, Inc.
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
2 years ago - By: Seeking Alpha
Panbela Therapeutics closes ~$9M public offering of shares (NASDAQ:PBLA)
2 years ago - By: Panbela Therapeutics, Inc.
Panbela Announces Closing of Approximately $9.0 Million Public Offering
2 years ago - By: Panbela Therapeutics, Inc.
Panbela Announces Closing of Approximately $9.0 Million Public Offering
2 years ago - By: Panbela Therapeutics, Inc.
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
2 years ago - By: Panbela Therapeutics, Inc.
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
2 years ago - By: InvestorPlace
- Mentions:
ACON
SOFI
REVB
Why Is Aclarion (ACON) Stock Down 16% Today?
2 years ago - By: InvestorPlace
- Mentions:
REVB
ONMD
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
Please enable JavaScript to continue using this application.